Study-Unit Description

Study-Unit Description


TITLE Pharmacotherapeutics 2

LEVEL 05 - Postgraduate Modular Diploma or Degree Course



DESCRIPTION The study-unit presents an integration of scientific aspects of medicinal chemistry, drug action, pharmacokinetic and toxicology to the use of drugs in management of disease states. The application of evidence-based medicine to pharmacotherapeutics with the identification of benefits and limitations to patient populations and individual patients is presented.

Areas covered:
- Renal disease;
- Ophthalmology;
- Endocrinology;
- Cardiology;
- Neurology;
- Opioid addiction;
- Toxicology;
- Psychiatry;
- Pain management.

Study-unit Aims:

The study-unit focuses on the application of evidence-based knowledge and aims to exemplify application of knowledge and clinical judgement as is required in clinical pharmacy practice.

The study-unit aims:
- To provide an advanced up-to-date overview of principles of pharmacotherapeutics;
- To provide an integrated approach of skills and knowledge required to enable rational decision-making in patient therapeutic management within clinical pharmacy practice;
- To engage students in an interactive case-based learning experience in problem solving and therapeutic management.

Learning Outcomes:

1. Knowledge & Understanding:

By the end of the study-unit the student will be able to:
- Apply patient and population-specific data in the management of medication use processes for the identification, prevention, reporting and management of medication errors and adverse effects;
- Evaluate, analyse and synthesise information and knowledge available to undertake and propose sound decisions.

2. Skills:

By the end of the study-unit the student will be able to:
- Use effective oral and writtten communication skills to communicate with patients and other healthcare professionals on the rationale, safe and effective use of medicinal products.
- Manage medication knowledge, mitigate errors and support decision-making based on evidence-based sources including information technology.
- Demonstrate effective interpersonal and intergroup behaviours.
- Co-operate and collaborate with healthcare professionals and patients to provide individualised treatment and support patient care.
- Develop and support practice of clinical pharmacy and therapeutics enabling seamless patient care.

Main Text/s and any supplementary readings:

- Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan W, Williams BR. Koda-Kimble and Young's Applied Therapeutics. The Clinical Use of Drugs. Lippincott, Williams & Wilkins 2012.
- Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, Dipiro JT. Pharmacotherapy Principles and Practice. 3rd edition. McGraw Hill. 2013.
- DiPiro J, Talbert RL, Yee G, Matzke G, Wells B, Posey M. A pathophysiologic approach. 8th edition. McGraw Hill. 2011.
- McLeod HL, DeVane CL, Haga SB, Johnson JA, Knoell DL, Kolesar JM, McInerney JD, Rogers PD, Walker JR. Pharmacogenomics: Application to patient care. ACCP. 2009.
- Miller ML, Attridge RL, Moote R, Ryan L. Internal medicine: A guide to clinical therapeutics. McGraw Hill. 2012.

STUDY-UNIT TYPE Independent Online Learning and Tutorials

Assessment Component/s Assessment Due Resit Availability Weighting
Classwork SEM2 Yes 30%
Online Examination (2 Hours) SEM2 Yes 70%

LECTURER/S Lilian M. Azzopardi
Marise Gauci
Louise Grech
Jennifer Hanh-Tran Pham
Alan Lau
Maria Theresa Christina Mactal Haaf
Anthony Serracino Inglott

The University makes every effort to ensure that the published Courses Plans, Programmes of Study and Study-Unit information are complete and up-to-date at the time of publication. The University reserves the right to make changes in case errors are detected after publication.
The availability of optional units may be subject to timetabling constraints.
Units not attracting a sufficient number of registrations may be withdrawn without notice.
It should be noted that all the information in the description above applies to study-units available during the academic year 2020/1. It may be subject to change in subsequent years.